| dc.contributor.author | Hariyantoa, Timotius Ivan | |
| dc.contributor.author | Kurniawan, Andree | |
| dc.date.accessioned | 2020-09-10T18:53:51Z | |
| dc.date.available | 2020-09-10T18:53:51Z | |
| dc.date.issued | 2020-09 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S245184762030110X | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/2172 | |
| dc.description.abstract | The coronavirus disease 2019 (COVID-19) pandemic has caused a significant impact on all aspects of life. One of the comorbidities associated with severe outcome and mortality of COVID-19 is diabetes. Metformin is one of the drugs which is most commonly used for the treatment of diabetes patients. This study aims to analyze the potential benefit of metformin use in reducing the mortality rate from COVID-19 infection. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Metformin | en_US |
| dc.subject | Mortality | en_US |
| dc.subject | Coronavirus Infections | en_US |
| dc.subject | Diabetes Mellitus | en_US |
| dc.title | Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Candidate therapeutics RD | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Obesity Medicine | en_US |
